Brand Name for Linagliptin
Linagliptin is marketed under the brand names Tradjenta (in the United States and some other countries) and Trajenta (in Europe and other regions). 1, 2, 3
Available Formulations
- Single-agent formulation: Linagliptin 5 mg tablets are available as Tradjenta/Trajenta 1, 3
- Fixed-dose combination: Linagliptin/metformin is marketed as Jentadueto 3, 4
Key Distinguishing Characteristics of Linagliptin
Linagliptin is the first and only DPP-4 inhibitor that requires no dose adjustment for renal impairment of any degree, making it unique among its class. 5, 4
Pharmacokinetic Advantages
- Predominantly non-renal elimination: Approximately 95% is eliminated via feces, with only 5% excreted renally 5, 6
- Single-strength dosing: 5 mg once daily for all patients, regardless of renal function, hepatic function, age, or body weight 1, 5
- No dose adjustment required in patients with eGFR <30 mL/min/1.73 m² or on dialysis 7, 1
Clinical Context
While linagliptin (Tradjenta/Trajenta) is an effective DPP-4 inhibitor with excellent renal safety, for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria, GLP-1 receptor agonists or SGLT2 inhibitors are preferred over any DPP-4 inhibitor due to proven cardiovascular and renal benefits. 7, 8
Linagliptin demonstrated cardiovascular safety but no cardiovascular benefit in the CARMELINA trial (HR 1.02; 95% CI 0.89-1.17 for major adverse cardiovascular events). 9, 7